Beranda › Mieloma Multipel › North Carolina › Durham
Uji klinis Mieloma Multipel di Durham, NC
37 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Menerima pesertaFase 3
- Research Site, Chapel Hill · 10 mi jauhnya
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Menerima pesertaFase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Menerima pesertaFase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Menerima pesertaFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi jauhnya
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi jauhnya
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi jauhnya
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Menerima pesertaFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi jauhnya
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Menerima pesertaFase 1/2
- GSK Investigational Site, Chapel Hill · 10 mi jauhnya
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Menerima pesertaFase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Menerima pesertaFase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Menerima pesertaFase 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi jauhnya
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Menerima peserta
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Menerima pesertaFase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Menerima pesertaFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi jauhnya
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi jauhnya
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Menerima pesertaFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi jauhnya
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Menerima pesertaFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Menerima pesertaFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi jauhnya
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Menerima pesertaFase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Menerima pesertaFase 2
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Menerima pesertaFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Menerima pesertaFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi jauhnya
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Menerima pesertaFase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi jauhnya
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Menerima pesertaFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi jauhnya
Registry for Adults With Plasma Cell Disorders (PCD's)
Menerima pesertaStudi observasional
- North Carolina Cancer Hospital, Chapel Hill · 10 mi jauhnya
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Menerima pesertaFase 1
- Duke University Health System (DUHS), Durham
Uji klinis Mieloma Multipel di kota lain
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
- Seattle, WA22 studi
Studi lain di Durham
- Kanker Payudara63 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Kanker Metastatik33 studi
- Leukemia Mieloid Akut33 studi
- Kanker Paru32 studi
- Kanker Prostat32 studi
- Kanker Kolorektal28 studi
- Leukemia Limfositik Kronis27 studi
- Kanker Ovarium27 studi
- Gagal Jantung26 studi
- Kanker Pankreas24 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.